Ruiz et al. bDMARD/tsDMARD use in RA after breast cancer. Low use, 15.5% on bDMARD, 1.5% on tsDMARD. Stable use over last 10 years @rheumnow #ACR22 Abstr#0080
Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer - ACR Meeting Abstracts
